First Wave BioPharma Inc. (NASDAQ:FWBI) shares traded 55.17% higher at $0.45 on Wall Street last session.
FWBI stock price is now -41.07% away from the 50-day moving average and -84.68% away from the 200-day moving average. The market capitalization of the company currently stands at $3.22M.
In other news, CASAMENTO CHARLES J, Director sold 6,053 shares of the company’s stock on Aug 31. The stock was sold for $1,816 at an average price of $0.30. Upon completion of the transaction, the Director now directly owns 6,108 shares in the company, valued at $2748.6. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 03, President and CEO SAPIRSTEIN JAMES sold 3,349 shares of the business’s stock. A total of $5,157 was realized by selling the stock at an average price of $1.54. This leaves the insider owning 36,161 shares of the company worth $16272.45. Insiders disposed of 10,648 shares of company stock worth roughly $4791.6 over the past 1 year. A total of 0.77% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FWBI stock. A new stake in First Wave BioPharma Inc. shares was purchased by VANGUARD GROUP INC during the first quarter worth $7,000.
First Wave BioPharma Inc. (NASDAQ: FWBI) opened at $0.3182 on Tuesday. During the past 12 months, First Wave BioPharma Inc. has had a low of $0.27 and a high of $34.30. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 0.70, and a quick ratio of 0.70. The fifty day moving average price for FWBI is $0.7398 and a two-hundred day moving average price translates $2.9087 for the stock.
The latest earnings results from First Wave BioPharma Inc. (NASDAQ: FWBI) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$1.89, missing analysts’ expectations of -$1.04 by -0.85. This compares to -$52.08 EPS in the same period last year. The company reported revenue of $4.18 million for the quarter, compared to $5.41 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -22.64 percent.
First Wave BioPharma Inc.(FWBI) Company Profile
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn’s disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
